My Day. My Rights. My Future.

No images? Click here

GAP-f

GAP-f Newsletter | World Children’s Day 2026

Dear GAP-f Members and Partners,

Progress is not always measured in big milestones. Sometimes, it is in the priorities we keep alive, the partnerships we build and the barriers we help remove.

At GAP-f, our ambition is clear: to make sure children are not an afterthought in the development and access of medicines designed for them. Across the entire life cycle – from identifying the medicines children need most, to generating evidence, supporting product development and accelerating access – we are working together to turn this ambition into action.

Our focus has been on putting the GAP-f 2025–2030 strategy into practice and making progress against it. We do so in a challenging global health landscape, where resources are stretched and priorities are shifting. Yet this is precisely when we must keep asking: how can children ever be considered a lower priority?

This World Children’s Day, we celebrate what our network is achieving together, thank our partners, WHO technical departments and colleagues across the wider community, and look ahead to what more we can do. Because every child deserves medicines designed with their needs in mind – and making that a reality takes all of us.

 

New collaborations

A growing network, a stronger collective effort

GAP-f continues to expand, and we welcome three new partners, bringing our membership to 34 network members.

Rosalind & Morris Goodman Family Pediatric Formulations Centre | TDR, the Special Programme for Research and Training in Tropical Diseases | conect4children (c4c)

The Rosalind and Morris Goodman Family logo
TDR logo
C4C logo

From priorities to progress

 Across the product life cycle, GAP-f and its partners are working to ensure that children get the medicines they need.

 

Prioritizing the medicines children need most

Launch of GAP-f Product portfolio

Through Paediatric Drug Optimization (PADO) exercises, we bring experts and partners together to identify the greatest treatment gaps and agree where action is most urgently needed. This year, with leadership from WHO Technical departments, WHO convened PADO exercises for HIV, TB and Leprosy. Outcomes from all PADO processes undertaken to date are now consolidated in a dedicated GAP-f product portfolio which you can access here!

Generating better evidence

Children need to be included in clinical research. GAP-f has mapped paediatric clinical research sites worldwide to identify existing capacity, strengthen collaboration and help guide future investment. View the Map here.

GAP-f has launched a new knowledge portal to support the inclusion of children in clinical trials. Bringing together practical guidance, international guidelines and the latest research, the portal aims to strengthen the design, implementation and oversight of trials involving neonates, children and young people. It will be regularly updated as the field evolves. Check out the portal here!

Optimizing clinical trial design to accelerate evidence generation

Prevention and treatment of respiratory suncytial virus disease among children

How can we speed up the generation of high-quality evidence to inform approval, policy and use of novel medicines?

The RSV workshop series illustrated how clinical trial design must keep pace with innovation and a changing public health landscape. WHO convened researchers, regulators, industry, and policymakers to align on the evidence needed to accelerate the development, approval, and access of RSV monoclonal antibodies and antiviral treatments for children. The consultations focused on pragmatic study design pathways, defining key endpoints, and identifying the evidence required to inform regulatory and policy decisions across settings.

Read the report here

 

Getting medicines to children 

 
regional workshop on strengthening the paediatric medicines ecosystem in the ASEAN region

Innovation only matters when it reaches the children who need it. In May 2026, WHO and its GAP-f partners convened a regional workshop on strengthening paediatric medicines ecosystems in the ASEAN region, bringing together stakeholders from four pilot countries to identify key challenges and practical solutions. A new report from the workshop captures the findings and outlines opportunities to strengthen national paediatric medicines ecosystems, helping countries translate global priorities and evidence into context-specific action. 

 

Highlights from WHO 

 
Global Tuberculosis report

The Global tuberculosis report for 2026 is now available!

The report provides an overview of the global TB epidemic and progress in prevention, diagnosis and treatment. Drawing on data from 187 countries and areas, representing over 99% of the world’s population and TB cases, it presents the latest estimates of disease burden and progress towards global targets. Data from this report remind us how tuberculosis in children must remain a priority of our collaborative action.

 

How do we ensure medicines are designed with children's needs in mind?

WHO's new guidance, Development of Paediatric Medicines: Points to Consider in Formulation (TRS 1067, Annex 8), provides practical advice on developing formulations suitable for children.A useful resource for everyone working in child health, pharmaceutical development and regulatory science.

Explore the WHO guidance | Download the PDF

 

Key Publications

GAP-f and its partners have contributed to important peer-reviewed publications reflecting the Network’s technical and policy leadership:

Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children - Lancet Child Adolesc Health 2026 Oct;10(10):755-764. doi: 10.1016/S2352-4642(26)00159-8.

Accelerating the clinical development of treatments for dengue: WHO dengue therapeutics landscape analysis and target product profiles - Lancet Microbe. 2027 May 19:101451. doi: 10.1016/j.lanmic.2026.101451. Epub ahead of print. PMID: 42685738.

Trials, tribulations, and formulations in access to new TB drugs for children: learning from rifapentine - IJTLD Open. 2026 Oct 12;3(10):611-617. doi: 10.5588/ijtldopen.26.0263. PMID: 42866592; PMCID: PMC13657021.

Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial-Lancet HIV. 2026 Oct;13(10):e702-e712. doi: 10.1016/S2352-3018(26)00168-2. Epub 2026 Sep 7. PMID: 42705257.

The global landscape of pediatric monoclonal antibody (mAb) clinical trials: an analysis of ClinicalTrials.gov. Front. Pediatr. 14:1846142. doi: 10.3389/fped.2026.1846142. 

 
Divider line

Partners Board

Dndi logo

Understanding dengue through clinical experience:

DNDi shares a clinicians' perspectives on dengue and the need for better treatment options.

Dengue video from Dndi
PATA logo

Making treatment gaps visible:

PATA's explainer video, The Bitter Pill: Bridging the Treatment Gap for Children, highlights the challenges children face in accessing appropriate treatment.

PATA video on needs of child appropriate medicines

Giving newborns a chance to live

Every newborn deserves a healthy start. But antibiotic resistance makes life-threatening infections such as neonatal sepsis increasingly difficult to treat. In Ghana, healthcare professionals are contributing to the NeoSep1 global clinical trial, led by GARDP and partners, to evaluate new antibiotic treatment options and improve care for newborns.

🎥 Watch healthcare professionals share why research into effective antibiotics is essential to protecting newborn lives and tackling drug resistance.

Giving newborns a chance to live
Medicines for Malaria Venture
 

Better malaria treatment for babies: Coartem® Baby was named Medicines for Malaria Venture's Project of the Year 2025, recognising progress in developing treatments specifically for young children.

Read more – MMV

Penta logo

One tablet, dissolved in water : making HIV treatment fit a child’s life

Children living with HIV deserve medicines designed around their needs. Findings from the UNIVERSAL-1 trial, part of GAP-f’s first product-development project, provide the safety and dosing evidence to advance a new, water-dispersible combination tablet (DTG/FTC/TAF) towards regulatory review. The formulation could offer young children and their caregivers a simpler, more practical daily treatment option. Read more here.

Closing the treatment gap for preschoolers

An estimated 50 million preschoolers worldwide, most in sub-Saharan Africa, have long lacked age-appropriate treatment for schistosomiasis (SCH). To fill this treatment gap, Arpraziquantel (arPZQ), a new treatment for preschool-aged children at risk of schistosomiasis, is now available, with pilots currently underway or recently completed in Côte d’Ivoire, Kenya, Senegal, Tanzania and Uganda. Over the past 18 months, more than 60,000 preschoolers have received the treatment through community-based mass drug administration or individual case management. In Tanzania, a recent economic evaluation study found that early SCH prevention through arPZQ generates a 16-fold return-on-investment when taking into account long-term health and socio-economic outcomes. To catalyse the scale up of arPZQ across Africa, the Arpraziquantel Access Alliance was launched in October 2026. It is co-chaired by UNDP and AUDA-NEPAD and includes participation from national NTD programmes, technical and development partners and funders.

Medicines Patent Pool

MPP’s open and free Long-Acting therapeutics Patents and Licences database, known as LAPaL, now allows users, through its clinical trials visualisation features, to gain insights on the inclusion of neonates, infants, children and, adolescents in clinical trials of a large number of long-acting products for multiple therapeutic areas of global public health importance (such as HIV, RSV, STIs, TB, and several NCDs). 

The screenshot attached showcases this feature, as applied to long-acting cabotegravir for HIV prevention, for which two clinical trials are listed as involving neonates and infants. MPP encourages GAP-f partners to explore the database, share any information that may be missing, and suggest new products or technologies for inclusion.

LAPAL
 

Keeping children at the centre. Today and every day.

Resources may be constrained. Priorities may shift. But children's right to appropriate medicines must not.

GAP-f will continue bringing partners together, connecting expertise and accelerating action so that children are not left behind.

My Day. My Rights. My Future.

#WorldChildrensDay #BetterMedsForKids #GAPf

 
 
TwitterLinkedInWebsite
 
GAP-f logo
  Tweet 
  Share 
  Forward 

GAP-f Network

GAP-f is WHO hosted network created to respond to the paediatric treatment gap

You are receiving this email because you have subscribed to the mailing list

Preferences  |  Unsubscribe